{"resourceType":"ValueSet","id":"2.16.840.1.113762.1.4.1032.61","meta":{"versionId":"9","lastUpdated":"2018-05-09T01:07:38.000-04:00"},"text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\">\n      <h2>Immunotherapy</h2>\n      <p>This value set includes codes from the following code systems:</p>\n      <ul>\n        <li>Include these codes as defined in \n          <code>http://www.icd10data.com/icd10pcs</code>\n          <table class=\"none\">\n            <tr>\n              <td>\n                <b>Code</b>\n              </td>\n              <td>\n                <b>Display</b>\n              </td>\n            </tr>\n            <tr>\n              <td>XW03351</td>\n              <td>Introduction of Blinatumomab Antineoplastic Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 1</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>XW033C3</td>\n              <td>Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 3</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>XW04351</td>\n              <td>Introduction of Blinatumomab Antineoplastic Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 1</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>XW043C3</td>\n              <td>Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 3</td>\n              <td/>\n            </tr>\n          </table>\n        </li>\n      </ul>\n    </div>"},"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.61","version":"20180509","name":"Immunotherapy","status":"active","date":"2018-05-09T01:00:04-04:00","publisher":"MITRE Steward","compose":{"include":[{"system":"http://www.icd10data.com/icd10pcs","concept":[{"code":"XW03351","display":"Introduction of Blinatumomab Antineoplastic Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 1"},{"code":"XW033C3","display":"Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 3"},{"code":"XW04351","display":"Introduction of Blinatumomab Antineoplastic Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 1"},{"code":"XW043C3","display":"Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 3"}]}]}}